Recent Quotes
My Watchlist
Indicators
Local Stocks
NewsOK Local Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ: REGN )

1,036.52 +9.97 (+0.97%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 14, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 353,918
Open 1,024.30
Bid (Size) 1,036.87 (1)
Ask (Size) 1,046.00 (1)
Prev. Close 1,026.55
Today's Range 1,017.96 - 1,042.66
52wk Range 684.80 - 1,042.66
Shares Outstanding 91,779,465
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Regeneron's Dupixent COPD Sales To Reach $20B By 2026, Analyst Sees Larger Addressable Market
Analyst projects Regeneron's Dupixent to drive COPD sales surge, envisioning $20B market by 2026 on larger addressable market. 
Via Benzinga
Why It's A New Day For COPD Patients — And Regeneron, Sanofi, Verona Stocks
The companies are closing in on the finish line for two new COPD treatments. 
Via Investor's Business Daily

Performance

YTD
+14.53%
+14.53%
1 Month
+7.08%
+7.08%
3 Month
+7.98%
+7.98%
6 Month
+21.82%
+21.82%
1 Year
+32.37%
+32.37%

More News

Read More
Why Big-Name Biotech Regeneron Pharma Just Joined The 1,000-Club
Via Investor's Business Daily
Peering Into Regeneron Pharmaceuticals's Recent Short Interest
Via Benzinga
Kevzara® (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis (pJIA)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Competitor Analysis: Evaluating Regeneron Pharmaceuticals And Competitors In Biotechnology Industry
Via Benzinga
Navigating 14 Analyst Ratings For Regeneron Pharmaceuticals
Via Benzinga
2 Biotech Stocks to Buy in May
Via The Motley Fool
Goldman Sachs Optimistic About Regenxbio's Gene Therapy Pipeline, Sees Over 160% Upside
Via Benzinga
Stock Split Watch: 3 Growth Stocks That Could Be Next
Via The Motley Fool
What's Going On With FibroGen Stock Tuesday?
Via Benzinga
Exposures Product Safety
FibroGen Stock Is Surging After The Bell: What's Going On?
Via Benzinga
Exposures Product Safety
Here's How Much $100 Invested In Regeneron Pharmaceuticals 10 Years Ago Would Be Worth Today
Via Benzinga
(REGN) - Analyzing Regeneron Pharmaceuticals's Short Interest
Via Benzinga
FDA Extends Review Deadline For Regeneron/Sanofi's Dupixent For 'Smoker's Lungs' Disease
Via Benzinga
Exposures Product Safety
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
What's Going On With Biohaven Stock Wednesday?
Via Benzinga
After UnitedHealth Cyberattack, Drug Distributor Cencora Notifies Americans' Health Information Stolen In Data Breach In February
Via Benzinga
Topics Data Breach
Exposures Information Security
Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
3 Stocks That Have Turned $25,000 Into More Than $1 Million in 15 Years
Via The Motley Fool
Large Cap Biopharmaceuticals Performance
Via Talk Markets
Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in The New England Journal of Medicine
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
7 Biotech Stocks That Could Breathe New Life Into Your Portfolio
Via InvestorPlace
Bragar Eagel & Squire, P.C. Is Investigating Zymeworks, Regeneron, Jabil, and DoubleVerify and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.